Atossa Therapeutics to Present at the Q2 Investor Summit Conference
April 27 2022 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company seeking to develop innovative medicines
in areas of significant unmet medical need in oncology and
infectious diseases with a current focus on breast cancer and
COVID-19, today announces that Kyle Guse, Chief Financial Officer
and General Counsel, will present a corporate overview at the Q2
Investor Summit Conference. The conference is being held on May 3 –
4, 2022 at the Westin New York Grand Central Hotel.
Presentation Date: |
May 3,
2022 |
Time: |
10:15am ET |
Webcast: |
Atossa Therapeutics Presentation Link |
Mr. Guse will be available for one-on-one meetings. To request a
meeting and to register for the conference, click here:
https://www.meetmax.com/sched/event_83063/investor_reg_new.html?attendee_role_id=ISG_INVESTOR
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to develop innovative medicines in areas of
significant unmet medical need in oncology and infectious diseases
with a current focus on breast cancer and COVID-19. For more
information, please
visit www.atossatherapeutics.com.
FORWARD-LOOKING STATEMENTS DISCLAIMER
STATEMENTForward-looking statements in this press release,
which Atossa undertakes no obligation to update, are subject to
risks and uncertainties that may cause actual results to differ
materially from the anticipated or estimated future results,
including, without limitation, statements regarding the
satisfaction of closing conditions relating to the offering and the
anticipated use of proceeds from the offering, the risks and
uncertainties associated with any variation between interim and
final clinical results, actions and inactions by the FDA, the
outcome or timing of regulatory approvals needed by Atossa
including those needed to commence and continue studies of AT-H201,
AT-301 and Endoxifen, lower than anticipated rate of patient
enrollment, estimated market size of drugs under development, the
safety and efficacy of Atossa’s products, performance of clinical
research organizations and investigators, obstacles resulting from
proprietary rights held by others such as patent rights, whether
reduction in Ki-67 or any other result from a neoadjuvant study or
reduction of breast density will be approvable endpoints for oral
Endoxifen, and other risks detailed from time to time in Atossa’s
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
COMPANY CONTACT:
Atossa Therapeutics, Inc.Kyle Guse, CFO and General
CounselOffice: (866)
893-4927kyle.guse@atossainc.comINVESTOR
RELATIONS CONTACT:Core IROffice: (516)
222-2560ir@atossainc.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024